The tissue immune response, represented by spatial CD8+ cell density profiles, was another independent predictor: better BCSS was associated with the incidence of CD8+ cells in the IZ tumor or stroma aspect in ER+HER2– BC and TNBC patients, respectively. This evidence concerns the gene ERBB2 and breast cancer.